Compare BridgeBio Pharma Inc (BBIO) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares Core MSCI EAFE ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while iShares Core MSCI EAFE ETF trades at $100.75. The key difference: iShares Core MSCI EAFE ETF is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | IEFA | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $101.09 |
52-Week Low | $47.29 | $84.22 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
IEFA (iShares Core MSCI EAFE ETF) trades at $101.09, up 1.1% with a bullish technical signal from moving averages. The fund provides exposure to developed international markets excluding the US and Canada, with a competitive 0.07% expense ratio and 3.30% dividend yield. Recent news highlights its role in diversification strategies amid S&P 500 concentration concerns.
The outlook remains positive given international diversification benefits and potential Fed rate cut catalysts. Key risks include developed market monetary policy shifts and currency fluctuations. Analyst sentiment favors IEFA for its cost efficiency and income generation, though emerging market alternatives offer different growth profiles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
